KEWAUNEE SCIENTIFIC CP (KEQU) Fundamental Analysis & Valuation

NASDAQ:KEQUUS4928541048

Current stock price

37.35 USD
+0.49 (+1.33%)
Last:

This KEQU fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. KEQU Profitability Analysis

1.1 Basic Checks

  • KEQU had positive earnings in the past year.
  • In the past year KEQU had a positive cash flow from operations.
  • In multiple years KEQU reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: KEQU reported negative operating cash flow in multiple years.
KEQU Yearly Net Income VS EBIT VS OCF VS FCFKEQU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M 15M

1.2 Ratios

  • The Return On Assets of KEQU (6.30%) is better than 83.42% of its industry peers.
  • With an excellent Return On Equity value of 15.68%, KEQU belongs to the best of the industry, outperforming 89.84% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 12.17%, KEQU belongs to the best of the industry, outperforming 93.05% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for KEQU is in line with the industry average of 9.12%.
  • The last Return On Invested Capital (12.17%) for KEQU is above the 3 year average (9.90%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.3%
ROE 15.68%
ROIC 12.17%
ROA(3y)6.79%
ROA(5y)2.22%
ROE(3y)17.94%
ROE(5y)5.55%
ROIC(3y)9.9%
ROIC(5y)N/A
KEQU Yearly ROA, ROE, ROICKEQU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 30

1.3 Margins

  • KEQU has a better Profit Margin (3.85%) than 75.40% of its industry peers.
  • Looking at the Operating Margin, with a value of 6.95%, KEQU is in the better half of the industry, outperforming 73.80% of the companies in the same industry.
  • Looking at the Gross Margin, with a value of 28.93%, KEQU is doing worse than 74.87% of the companies in the same industry.
  • In the last couple of years the Gross Margin of KEQU has grown nicely.
Industry RankSector Rank
OM 6.95%
PM (TTM) 3.85%
GM 28.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.96%
GM growth 5Y12.54%
KEQU Yearly Profit, Operating, Gross MarginsKEQU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20

5

2. KEQU Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), KEQU is creating some value.
  • KEQU has about the same amout of shares outstanding than it did 1 year ago.
  • KEQU has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, KEQU has a worse debt to assets ratio.
KEQU Yearly Shares OutstandingKEQU Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M 2M 2.5M
KEQU Yearly Total Debt VS Total AssetsKEQU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 3.51 indicates that KEQU is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.51, KEQU is doing good in the industry, outperforming 71.12% of the companies in the same industry.
  • The Debt to FCF ratio of KEQU is 2.61, which is a good value as it means it would take KEQU, 2.61 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of KEQU (2.61) is better than 82.89% of its industry peers.
  • A Debt/Equity ratio of 0.62 indicates that KEQU is somewhat dependend on debt financing.
  • KEQU has a worse Debt to Equity ratio (0.62) than 65.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF 2.61
Altman-Z 3.51
ROIC/WACC1.56
WACC7.82%
KEQU Yearly LT Debt VS Equity VS FCFKEQU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 2.12 indicates that KEQU has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.12, KEQU is doing worse than 60.43% of the companies in the same industry.
  • A Quick Ratio of 1.45 indicates that KEQU should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.45, KEQU is not doing good in the industry: 64.17% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.12
Quick Ratio 1.45
KEQU Yearly Current Assets VS Current LiabilitesKEQU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

3

3. KEQU Growth Analysis

3.1 Past

  • The earnings per share for KEQU have decreased strongly by -37.07% in the last year.
  • KEQU shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.78%.
  • Measured over the past years, KEQU shows a quite strong growth in Revenue. The Revenue has been growing by 10.27% on average per year.
EPS 1Y (TTM)-37.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.31%
Revenue 1Y (TTM)30.78%
Revenue growth 3Y12.5%
Revenue growth 5Y10.27%
Sales Q2Q%3.32%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KEQU Yearly Revenue VS EstimatesKEQU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
KEQU Yearly EPS VS EstimatesKEQU Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 0.5 1 1.5

5

4. KEQU Valuation Analysis

4.1 Price/Earnings Ratio

  • KEQU is valuated reasonably with a Price/Earnings ratio of 8.81.
  • Based on the Price/Earnings ratio, KEQU is valued cheaper than 94.12% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of KEQU to the average of the S&P500 Index (27.66), we can say KEQU is valued rather cheaply.
Industry RankSector Rank
PE 8.81
Fwd PE N/A
KEQU Price Earnings VS Forward Price EarningsKEQU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, KEQU is valued cheaply inside the industry as 97.33% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, KEQU is valued cheaply inside the industry as 98.93% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 5.63
EV/EBITDA 5.6
KEQU Per share dataKEQU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • The decent profitability rating of KEQU may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. KEQU Dividend Analysis

5.1 Amount

  • No dividends for KEQU!.
Industry RankSector Rank
Dividend Yield 0%

KEQU Fundamentals: All Metrics, Ratios and Statistics

KEWAUNEE SCIENTIFIC CP

NASDAQ:KEQU (4/21/2026, 8:00:03 PM)

37.35

+0.49 (+1.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-11
Earnings (Next)06-23
Inst Owners42.06%
Inst Owner Change1.92%
Ins Owners15.69%
Ins Owner Change-1.37%
Market Cap107.19M
Revenue(TTM)287.75M
Net Income(TTM)11.08M
Analysts82.86
Price TargetN/A
Short Float %1.84%
Short Ratio7.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 8.81
Fwd PE N/A
P/S 0.37
P/FCF 5.63
P/OCF 4.75
P/B 1.52
P/tB 2.58
EV/EBITDA 5.6
EPS(TTM)4.24
EY11.35%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)6.64
FCFY17.78%
OCF(TTM)7.87
OCFY21.06%
SpS100.26
BVpS24.63
TBVpS14.46
PEG (NY)N/A
PEG (5Y)N/A
Graham Number48.4692 (29.77%)
Profitability
Industry RankSector Rank
ROA 6.3%
ROE 15.68%
ROCE 15.73%
ROIC 12.17%
ROICexc 13%
ROICexgc 17.14%
OM 6.95%
PM (TTM) 3.85%
GM 28.93%
FCFM 6.62%
ROA(3y)6.79%
ROA(5y)2.22%
ROE(3y)17.94%
ROE(5y)5.55%
ROIC(3y)9.9%
ROIC(5y)N/A
ROICexc(3y)12.02%
ROICexc(5y)N/A
ROICexgc(3y)13.16%
ROICexgc(5y)N/A
ROCE(3y)12.97%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.96%
GM growth 5Y12.54%
F-Score6
Asset Turnover1.64
Health
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF 2.61
Debt/EBITDA 1.67
Cap/Depr 55.94%
Cap/Sales 1.23%
Interest Coverage 4.36
Cash Conversion 85.86%
Profit Quality 171.98%
Current Ratio 2.12
Quick Ratio 1.45
Altman-Z 3.51
F-Score6
WACC7.82%
ROIC/WACC1.56
Cap/Depr(3y)110.02%
Cap/Depr(5y)97.64%
Cap/Sales(3y)1.65%
Cap/Sales(5y)1.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.31%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)30.78%
Revenue growth 3Y12.5%
Revenue growth 5Y10.27%
Sales Q2Q%3.32%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.25%
FCF growth 3YN/A
FCF growth 5Y49.49%
OCF growth 1Y24.21%
OCF growth 3YN/A
OCF growth 5Y28.86%

KEWAUNEE SCIENTIFIC CP / KEQU Fundamental Analysis FAQ

What is the ChartMill fundamental rating of KEWAUNEE SCIENTIFIC CP (KEQU) stock?

ChartMill assigns a fundamental rating of 5 / 10 to KEQU.


What is the valuation status of KEWAUNEE SCIENTIFIC CP (KEQU) stock?

ChartMill assigns a valuation rating of 5 / 10 to KEWAUNEE SCIENTIFIC CP (KEQU). This can be considered as Fairly Valued.


Can you provide the profitability details for KEWAUNEE SCIENTIFIC CP?

KEWAUNEE SCIENTIFIC CP (KEQU) has a profitability rating of 6 / 10.


What is the valuation of KEWAUNEE SCIENTIFIC CP based on its PE and PB ratios?

The Price/Earnings (PE) ratio for KEWAUNEE SCIENTIFIC CP (KEQU) is 8.81 and the Price/Book (PB) ratio is 1.52.